For context on the timeline, tirzepatide weight loss timeline covers what to expect month by month
Transparent research-grade quality
Half-Life: The drug boasts an impressive plasma half-life of approximately 5 days due to a modified peptide structure, which includes a C20 fatty diacid moiety that enables binding to plasma albumin
A randomized controlled trial of dapagliflozin plus once-weekly exenatide versus placebo in individuals with obesity and without diabetes: metabolic effects and markers associated with bodyweight loss
The compounds discussed are investigational and, unless otherwise noted, have not been approved for human therapeutic use by Health Canada or any other regulatory body
GLP-1 receptor agonists, as established in earlier sections, independently produce average weight reductions of 15 to 22% of total body weight in the STEP and SURMOUNT trial programs [8,9]